**UAREB FORM 02(F) 2024: Informed Consent Assessment Form**

**STUDY PROTOCOL INFORMATION**

* **Study Protocol Title:**  
  CommunityLink: Community Extension Services Through Web Application for the University Of The Assumption
* **Principal Investigators:**  
  Aaron Joaquin P. Basilio, Mervie V. Isip, John Angelo M. Pabustan
* **Study Protocol Submission Date:**  
  July 18, 2025

**Essential Elements to be Filled:**

1. **Statement introducing the researcher(s) and that the study involves research:**
   * **Found in:** Page 1, Section A: Application Information
   * "The study involves research into the development and assessment of the 'CommunityLink' platform for community extension services."
2. **Statement describing the purpose of the study:**
   * **Found in:** Page 2, Section B: Study Protocol Synopsis
   * "The study aims to develop and assess a centralized, web-based platform, 'CommunityLink,' to improve data accuracy and visibility in documenting, tracking, and evaluating student participation in community extension programs."
3. **Study-related treatments and probability for random assignment:**
   * **Found in:** Page 4, Section B: Study Design
   * "The study will not involve random assignment or treatments. The experimental aspect involves the use of a digital platform for testing."
4. **Study procedures including all invasive procedures:**
   * **Found in:** Page 4, Section B: Study Design
   * "There are no invasive procedures involved. Participants will engage with the platform and complete a survey."
5. **Responsibilities of the participant:**
   * **Found in:** Page 4, Section B: Study Design
   * "Participants will engage with the platform for event registration and reporting tasks and will complete an online survey afterward."
6. **Expected duration and manner of participation in the study including terms and conditions of the data collection methodology/process:**
   * **Found in:** Page 3, Section B: Study Design
   * "Interaction with the platform will take 15-30 minutes, and the survey will take an additional 10-15 minutes."
7. **Approximate number of participants in the study:**
   * **Found in:** Page 4, Section B: Study Design
   * "At least 10% of students from participating departments will be invited to participate."
8. **Study aspects that are experimental:**
   * **Found in:** Page 4, Section B: Study Design
   * "The experimental aspect is the testing of the CommunityLink platform for managing community extension activities."
9. **Foreseeable risks to participant/embryo/fetus/nursing infant:**
   * **Found in:** Page 5, Section B: Study Design
   * "The risks are minimal, consisting mainly of privacy concerns and inconvenience due to time commitments."
10. **Risks from allowable use of placebo (as applicable):**

* **Found in:** Page 5, Section B: Study Design
* "N/A—this study does not use a placebo."

1. **Reasonably expected benefits or absence of direct benefit to participants:**

* **Found in:** Page 5, Section B: Study Design
* "Participants will benefit from seamless documentation of their community service, and enhanced tracking of hours and participation."

1. **Expected benefits to the community or to society, or contributions to scientific knowledge:**

* **Found in:** Page 5, Section B: Study Design
* "The broader community will benefit from more organized and accountable volunteer engagement."

1. **Description of post-study access to the study product or intervention that has been proven safe and effective:**

* **Found in:** Page 5, Section B: Study Design
* "The platform will continue to serve the University of the Assumption after the study concludes."

1. **Alternative procedures or treatment available to the participant:**

* **Found in:** Page 5, Section B: Study Design
* "N/A—this study involves only interaction with the platform, and no treatments or alternatives are being tested."

1. **Anticipated payment to the participant in the course of the study:**

* **Found in:** Page 5, Section B: Study Design
* "There is no payment or compensation for participation."

1. **Compensation for the participant or the participant’s family or dependents in case of disability or death resulting from study-related injuries:**

* **Found in:** Page 5, Section B: Study Design
* "No compensation is provided as the study involves minimal risk."

1. **Anticipated expenses to the participant in the course of the study:**

* **Found in:** Page 5, Section B: Study Design
* "There are no anticipated expenses for participants."

1. **Statement that participation is voluntary and may be withdrawn anytime without penalty or loss of benefit:**

* **Found in:** Page 5, Section B: Study Design
* "Participation is voluntary, and participants may withdraw at any time without penalty."

1. **For research involving children and adolescents, statement that consent will be obtained if the participant reaches legal age in the duration of the study:**

* **Found in:** Page 4, Section B: Study Design
* "N/A—this study involves only college students."

1. **Statement that the study monitor(s), auditor(s), the UAREB, and regulatory authorities will be granted direct access to participant’s medical records for purposes ONLY of verification of clinical trial procedures and data:**

* **Found in:** Page 5, Section B: Study Design
* "N/A—this study does not involve medical records."

1. **Statement that the records identifying the participant will be kept confidential and will not be made publicly available, to the extent permitted by law:**

* **Found in:** Page 5, Section B: Study Design
* "Participants' records will be kept confidential and will not be disclosed publicly."

1. **A description of the data protection plan:**

* **Found in:** Page 6, Section B: Study Design
* "Data will be encrypted, stored securely, and accessible only to the research team. It will be stored for three years and then deleted."

1. **Description of policy regarding the use of genetic tests and familial genetic information:**

* **Found in:** Page 5, Section B: Study Design
* "N/A—there is no genetic testing involved in this study."

1. **Possible direct or secondary use of participant’s medical records and biological specimens taken in the course of clinical care or in the course of this study:**

* **Found in:** Page 5, Section B: Study Design
* "N/A—no biological specimens are collected."

1. **Plans to destroy collected biological specimen at the end of the study:**

* **Found in:** Page 5, Section B: Study Design
* "N/A."

1. **Plans to develop commercial products from biological specimens:**

* **Found in:** Page 5, Section B: Study Design
* "N/A."

1. **Statement that the participant or participant’s legally acceptable representative will be informed in a timely manner if information becomes available that may be relevant to willingness of the participant to continue to participation:**

* **Found in:** Page 6, Section B: Study Design
* "Any relevant information will be shared with participants as needed."

1. **Statement describing that consent for participation is time-bound:**

* **Found in:** Page 6, Section B: Study Design
* "Consent is valid for the duration of the study, and re-consent will be obtained if necessary."

**Data Privacy Issues:**

1. **Measures against data breach:**

* **Found in:** Page 6, Section B: Study Design
* "Data encryption, two-factor authentication, and strong passwords are implemented to protect data."

1. **Statement describing the data subject’s right to be informed that their personal data will be collected and processed:**

* **Found in:** Page 6, Section B: Study Design
* "Participants will be informed of data collection and processing methods."

1. **Statement describing the data subject’s right to object or withhold consent to processing in case of changes or any amendment to the information supplied:**

* **Found in:** Page 6, Section B: Study Design
* "Participants can withdraw consent at any time without penalty."

1. **Statement describing extent of participant’s right to access his/her records:**

* **Found in:** Page 6, Section B: Study Design
* "Participants have the right to access their data upon request."

1. **Compensation or insurance or treatment entitlements of the participant in case of study-related injury:**

* **Found in:** Page 5, Section B: Study Design
* "There is no compensation for study-related injuries."

1. **Statement describing access of participant to the result of the study:**

* **Found in:** Page 6, Section B: Study Design
* "Results will be available to participants at the end of the study."

1. **Foreseeable circumstances and reasons under which participation in the study may be terminated:**

* **Found in:** Page 5, Section B: Study Design
* "Participation may be terminated if a participant withdraws or if the study site decides not to allow platform use."

1. **Sponsor, institutional affiliation of the investigators, and nature and sources of funds:**

* **Found in:** Page 6, Section B: Study Design
* "The University of the Assumption is the sponsor, and no external funding is listed."

1. **Statement whether the investigator is serving only as an investigator or as both investigator and the participant’s healthcare provider:**

* **Found in:** Page 6, Section B: Study Design
* "The investigators are solely conducting the research."

1. **Person(s) to contact in the study team for further information regarding the study and whom to contact in the event of study-related injury:**

* **Found in:** Page 6, Section B: Study Design
* "Contact details for the research team are provided."

1. **Statement that the UAREB Ethics Review Panel has approved the study, and may be reached for information regarding the rights of study participants, including grievances and complaints:**

* **Found in:** Page 6, Section B: Study Design
* "The UAREB is responsible for oversight, and contact details are provided."

1. **Comprehensibility of language used:**

* **Found in:** Page 6, Section B: Study Design
* "Clear and accessible language is used throughout the consent form."

**RECOMMENDED ACTION:**  
• **APPROVE**